Archive: Company News
Company News: Curetis’ Subsidiary Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance
— Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform
— Collaboration leverages Ares Genetics’ antibiotic resistance database ARESdb
— Short-term focus on repurposing existing antibiotics to treat infections with multi drug resistant pathogens
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), today announced that its wholly-owned subsidiary Ares Genetics GmbH signed a collaboration agreement with Sandoz to leverage Ares Genetics’ database on the genetics of antibiotic resistance, ARESdb, and the ARES Technology Platform for Sandoz’ anti-infective portfolio. Read more…
Company News: Curetis Sharpens Focus on Near-Term Strategic Value Drivers
— Business focus on U.S. commercialization, strategic partnering, Ares Genetics and asset monetization
— Reduction of net cash consumption by up to 50% (YoY) expected
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced an update on its strategic value creation priorities for 2019 and beyond. Read more…
Company News: Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine
— The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability
— Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible
Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study of the second-generation COP allergy vaccines based on its research collaboration with Mymetics SA, a leader in the research and development of virosome-based vaccines. Read more…
Company News: Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for the Treatment of Chronic Heart Failure
— Collaboration with Hannover Medical School (MHH)
Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH). Read more…